Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Immunocore Holdings plc
Headquarters: Abingdon, Oxon, United Kingdom
Website: http://www.immunocore.com
Year Founded: 2008
Status: Public
Industry Sector: HealthTechnology
CEO: Bahija Jallal, PhD
Number Of Employees: 493
Enterprise Value: $1,087,082,388
PE Ratio: -27.67
Exchange/Ticker 1: NASDAQ:IMCR
Exchange/Ticker 2: N/A
Latest Market Cap: $1,503,949,568
BioCentury | Jan 4, 2025
Management Tracks
Four companies announce new CFOs
Plus: Jia joins Grit Bio and Riley joins Avalo
BioCentury | Nov 20, 2024
Product Development
Biotechs now match pharma for FDA approvals
Half of FDA approvals are sponsored by biotechs; almost all are marketing in the U.S. themselves
BioCentury | Oct 22, 2024
Product Development
Newco trend watch: Clusters of launches point to areas undergoing derisking
Oligo delivery to the kidney, and two emerging use cases for T cell engagers, each get newcos; most with mega-
BioCentury | Sep 13, 2024
Data Byte
PanTera largest Belgian A round to date
Only nine other biotechs have raised over $25 million since 2015
BioCentury | Aug 30, 2024
Management Tracks
Di Donato to leave Immunocore
Plus: FDA’s Mantha, Fakhouri and Liu lead CDER’s AI Council, and an update from BC Platforms
BioCentury | May 21, 2024
Emerging Company Profile
Crossbow: Tumor antigen targeting beyond cell surface proteins, at scale
Through antibody targeting of HLA-peptide complexes, the MPM-built biotech is turning intracellular tumor antigens into handles for T cell engagers
BioCentury | Dec 1, 2023
Management Tracks
Eliot Forster named Levicept CEO
Plus: Sirnaomics promotes Lebel to CMO and updates from Enavate Sciences, Avoro Ventures, Eagle, Calliditas, 20Med
BioCentury | Sep 22, 2023
Management Tracks
Shields leaving BenevolentAI as CEO
Plus: Berns named interim CMO at Faron, and updates from Coave, Maxion, Nanoscope and Patient Square
BioCentury | Aug 30, 2023
Finance
IPO superstars
Back to School 2023: Six companies with NASDAQ IPOs since 2021 have more than doubled their market caps. Another four met the doubling mark via M&A
BioCentury | May 18, 2023
Management Tracks
Roche’s Perettie to head cell therapy at Kite
Plus: Ochre appoints Forster as chairperson and updates from Women In Bio, Verismo and MIG
Items per page:
1 - 10 of 23